Who
Dominick Colangelo
Director
Company insider
Files Form 4 as: Director, Trevi Therapeutics; President and CEO, Vericel; EVP Corporate Dev & Operations, Oscient Pharmaceuticals.
In numbers
- Trades disclosed
- 291
- Buys
- 2
- Sells
- 41
- Bought
- $53K
- Sold
- $35.5M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 27 Feb 2006
- Last trade
- 3 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 4 Jun 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —18,250 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —18,250 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code F | $336K8,824 at $38.09 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —18,250 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —18,250 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —18,250 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —18,250 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —18,250 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —18,250 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code F | $336K8,824 at $38.09 | filing |
| 19 Feb 2026filed 20 Feb 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —182,500 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —73,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —182,500 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code A | —73,000 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —18,250 | filing |
| 18 Feb 2026filed 20 Feb 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code M | —11,700 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | VCEL VericelBiotechnology | SEC FORM 4 Code F | $212K5,657 at $37.41 | filing |
| 18 Feb 2026filed 20 Feb 2026 | VCEL Vericeloption or derivative · Biotechnology | SEC FORM 4 Code M | —18,250 | filing |
News
No headline names them, or the companies they trade most, lately.